A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Astellas Pharma Inc
Eisai Inc.
Nouscom SRL
Eisai Inc.
Werewolf Therapeutics, Inc.
Transgene
GlaxoSmithKline
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Eli Lilly and Company
Mirati Therapeutics Inc.
Proton Collaborative Group
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
University of Rochester
Novartis
Bayer
BioAtla, Inc.
Bristol-Myers Squibb
University Medical Center Groningen
A2 Biotherapeutics Inc.
Servier
iOnctura
Columbia University
Genmab
Takara Bio Inc.
AstraZeneca
Salubris Biotherapeutics Inc
Seqker Biosciences, Inc.
ENB Therapeutics, Inc
Erasca, Inc.
Mural Oncology, Inc
SillaJen, Inc.